Centre of Evidence Based Dermatology
BlisteringDiseases

Blistering Diseases

These rare skin conditions cause blisters to form on various parts of the body. 
 

Research overview

Pemphigoid and pemphigus are uncommon blistering skin diseases.

The diseases arise when a person’s own immune system, which serves as the body’s defence system against viruses and harmful bacteria, attacks components of the skin and/or mucous membranes (such as mouth, nose, and eyes). This causes blisters to form, often accompanied by intense itchiness and/or pain. Severe forms of the disease may even be life-threatening.

Unfortunately, current treatment options are limited and often cause severe side effects. In order to improve the care of people with pemphigus and pemphigoid increased awareness and understanding of the diseases as well high-quality research into the management is required.

 
 

All projects

ProjectDescriptionFundingStatus
The association between the COVID-19 vaccine and skin conditions The projects examines whether COVID-19 vaccines are associated with the risk of bullous pemphigoid, herpes zoster (shingles), and urticaria (hives). 

NIHR School for Primary Care Research 

 In progress Paper 1 submitted Paper 2 in write-up
Exploring the care pathway to diagnosis for patients with autoimmune blistering diseases: a qualitative study of General Practitioners’ views Qualitative interview study exploring GP perspectives on recognising and referring autoimmune blistering diseases

NIHR School for Primary Care Research

 Writing up
The association between prescription drugs and vaccines commonly prescribed for older people and bullous pemphigoid: a UK population-based study. To examine whether drugs commonly prescribed in older people are associated with increased Bullous Pemphigoid risk using routinely collected electronic healthcare records

NIHR RfPB

NIHR202781

 Complete,
Informing trial development in blistering diseases Validation of blistering disease recording in routinely collected healthcare data from general practices, updating the epidemiology of bullous pemphigoid, describing current oral prednisolone prescribing in primary care, and informing trial feasibility NIHR RfPB 20033 Published:
paper 1,
paper 2
Pemphigus and pemphigoid Priority Setting Partnership (PEM PSP) The PEM PSP aims to identify treatment uncertainties important to those affected by auto-immune blistering diseases Nottingham Hospitals Charity Complete
The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) study Examined whether doxycycline  would be a good alternative to prednisolone for treating bullous pemphigoid. NIHR HTA - 06/403/51 Published

Centre of Evidence Based Dermatology

The University of Nottingham
Applied Health Research Building
University Park, Nottingham
NG7 2RD


telephone: +44 (0) 115 84 68631
email: cebd@nottingham.ac.uk